This clinical study delved into assessing the effectiveness of VERISOL® in reducing wrinkles—a vital parameter in gauging the efficacy of collagen peptides in addressing signs of aging. The focus was on understanding the impact of VERISOL® on wrinkle reduction among women aged 45-65.

Similar to the first clinical study, this investigation adopted a double-blind, placebo-controlled trial design. A total of 114 women participated in the study, with each group assigned to either a daily intake of 2.5g VERISOL® or a placebo. The trial spanned 8 weeks, with measurements taken at pivotal intervals—4 and 8 weeks into the study, followed by a 4-week washout period.

• The outcomes were compelling, showcasing a significant reduction in wrinkle volume among those who consumed 2.5g of VERISOL® compared to the placebo group.
• Furthermore, the study identified a substantial increase in the concentration of pro-collagen, emphasizing the positive impact of VERISOL® on collagen synthesis.
• Additionally, a significant increase in skin elastin was observed, further affirming the comprehensive benefits of VERISOL® in promoting skin health.

This study, a valuable contribution to the understanding of collagen peptide efficacy, reinforces VERISOL®'s role in reducing wrinkles and enhancing key components of skin structure.